Literature DB >> 9534679

Persistence of protective immunity after postexposure prophylaxis of varicella with oral aciclovir in the family setting.

T Yoshikawa1, S Suga, T Kozawa, S Kawaguchi, Y Asano.   

Abstract

The persistence of protective immunity after postexposure prophylaxis against varicella using oral aciclovir was evaluated in the family setting. Sixty one of 78 recipients of oral aciclovir were assessed by questionnaire, and 13 of 61 were evaluated for serum antibody to varicella zoster virus (VZV) using the fluorescent antibody to membrane antigen method. The observation period ranged from 33 to 50 months. None of those (n = 44) who had initially seroconverted to VZV after aciclovir prophylaxis developed breakthrough varicella. All 13 who had serology repeated still had titres > or = 4. Antibody titres in those who had histories of re-exposure to the virus were significantly higher than in those who had not (p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534679      PMCID: PMC1717446          DOI: 10.1136/adc.78.1.61

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  Modification of chicken pox in family contacts by administration of gamma globulin.

Authors:  A H ROSS
Journal:  N Engl J Med       Date:  1962-08-23       Impact factor: 91.245

2.  Protection against varicella in family contacts by immediate inoculation with live varicella vaccine.

Authors:  Y Asano; H Nakayama; T Yazaki; R Kato; S Hirose
Journal:  Pediatrics       Date:  1977-01       Impact factor: 7.124

3.  Acyclovir prophylaxis of varicella after household exposure.

Authors:  Y C Huang; T Y Lin; C H Chiu
Journal:  Pediatr Infect Dis J       Date:  1995-02       Impact factor: 2.129

4.  Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir.

Authors:  Y Ishida; H Tauchi; A Higaki; Y Yokota-Outou; K Kida
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

5.  The pediatric resident susceptible to varicella: providing immunity through postexposure prophylaxis with oral acyclovir.

Authors:  C B White; W Z Hawley; D J Harford
Journal:  Pediatr Infect Dis J       Date:  1994-08       Impact factor: 2.129

6.  Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays.

Authors:  Y Asano; P Albrecht; L K Vujcic; G V Quinnan; K Kawakami; M Takahashi
Journal:  Pediatrics       Date:  1983-09       Impact factor: 7.124

7.  Comparison of specific immunities to varicella-zoster virus following post-exposure prophylaxis of varicella by oral acyclovir observed in a family.

Authors:  Y Asano; S Suga; T Yoshikawa
Journal:  Acta Paediatr Jpn       Date:  1996-12

8.  Dose-dependent effects of oral acyclovir in the incubation period of varicella.

Authors:  S Suga; T Yoshikawa; T Yazaki; T Ozaki; Y Asano
Journal:  Acta Paediatr       Date:  1996-12       Impact factor: 2.299

9.  Postexposure prophylaxis of varicella in family contact by oral acyclovir.

Authors:  Y Asano; T Yoshikawa; S Suga; I Kobayashi; T Nakashima; T Yazaki; T Ozaki; A Yamada; J Imanishi
Journal:  Pediatrics       Date:  1993-08       Impact factor: 7.124

10.  Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.

Authors:  S Suga; T Yoshikawa; T Ozaki; Y Asano
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

  10 in total
  2 in total

Review 1.  Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.

Authors:  Martina Prelog; Jörn Schönlaub; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-11-15       Impact factor: 3.714

Review 2.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.